{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:25:20Z","timestamp":1791181520550,"version":"4.1.0"},"reference-count":32,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Immune and nonimmune microenvironmental factors play a critical role in the progression, transformation, and resistance to therapy in follicular lymphoma (FL). A recent increase in our understanding of the role of microenvironment in FL biology has led to the development of novel therapeutic strategies targeting the nonimmune and immune microenvironment. These include immunomodulatory drugs, immune checkpoint inhibitors, immnunoconjugates, and small-molecule inhibitors with an impact on the microenvironment in addition to direct antitumor activity. These agents are now at different stages of clinical development, ranging from early clinical trials in relapsed disease to phase 3 studies in the upfront setting, including combinations with other agents such as monoclonal antibodies and chemotherapy. It is important to recognize that, although the current upfront therapy of FL is associated with favorable outcomes in the majority of patients, a significant proportion experience early disease progression and develop treatment resistance and transformation to aggressive lymphoma. Although the development of \u201cchemo-free\u201d combinations using drugs targeting the microenvironment offers a promising approach to minimize toxicity, the identification of patients at risk of relapse and the use of biomarkers allowing the personalization of therapy will likely play a major role in the development of maintenance strategies. Against this landscape of currently available therapy options, this chapter discusses the clinical status of therapies targeting the microenvironment in FL.<\/jats:p>","DOI":"10.1182\/asheducation-2014.1.169","type":"journal-article","created":{"date-parts":[[2014,11,24]],"date-time":"2014-11-24T18:39:03Z","timestamp":1416854343000},"page":"169-173","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Therapeutic targeting of microenvironment in follicular lymphoma"],"prefix":"10.1182","volume":"2014","author":[{"given":"Grzegorz S.","family":"Nowakowski","sequence":"first","affiliation":[{"name":"Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"8","key":"2019111704122038700_B1","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","article-title":"Follicular lymphoma in the United States: first report of the national LymphoCare study","volume":"27","author":"Friedberg","year":"2009","journal-title":"J Clin Oncol"},{"issue":"26","key":"2019111704122038700_B2","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","article-title":"Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource","volume":"31","author":"Link","year":"2013","journal-title":"J Clin Oncol"},{"key":"2019111704122038700_B3","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1182\/asheducation-2013.1.561","article-title":"Dissecting follicular lymphoma: high versus low risk","volume":"2013","author":"Smith","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"21","key":"2019111704122038700_B4","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111704122038700_B5","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/CCO.0b013e32833d5938","article-title":"Implications of the tumor microenvironment on survival and disease response in follicular lymphoma","volume":"22","author":"Gribben","year":"2010","journal-title":"Curr Opin Oncol"},{"issue":"4","key":"2019111704122038700_B6","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3109\/10428194.2011.637211","article-title":"The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma","volume":"53","author":"Wilcox","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"2019111704122038700_B7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1756-8722-2-36","article-title":"Mechanism of action of lenalidomide in hematological malignancies","volume":"2","author":"Kotla","year":"2009","journal-title":"J Hematol Oncol"},{"issue":"21","key":"2019111704122038700_B8","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1182\/blood-2009-04-217687","article-title":"Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy","volume":"114","author":"Ramsay","year":"2009","journal-title":"Blood"},{"issue":"32","key":"2019111704122038700_B9","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1200\/JCO.2008.21.1169","article-title":"Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's lymphoma","volume":"27","author":"Witzig","year":"2009","journal-title":"J Clin Oncol"},{"issue":"16","key":"2019111704122038700_B10","doi-asserted-by":"crossref","first-page":"5984","DOI":"10.1158\/1078-0432.CCR-05-0577","article-title":"Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model","volume":"11","author":"Hernandez-Ilizaliturri","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2019111704122038700_B11","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ajh.21468","article-title":"Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo","volume":"84","author":"Zhang","year":"2009","journal-title":"Am J Hematol"},{"issue":"1","key":"2019111704122038700_B12","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2141.2007.06841.x","article-title":"Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo","volume":"140","author":"Reddy","year":"2008","journal-title":"Br J Haematol"},{"issue":"14","key":"2019111704122038700_B13","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells","volume":"14","author":"Wu","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"22","key":"2019111704122038700_B14","first-page":"1679","article-title":"R2: Preliminary results of a phase II study of lenalidomide and rituximab in relapsed\/ refractory indolent non-Hodgkin's lymphoma [abstract]","volume":"114","author":"Dutia","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"2019111704122038700_B15","first-page":"8000","article-title":"CALGB 50401: A randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma [abstract]","volume":"30","author":"Leonard","year":"2012","journal-title":"ASCO Annual Meeting Abstracts"},{"issue":"22","key":"2019111704122038700_B16","first-page":"901","article-title":"Lenalidomide and rituximab for untreated indolent lymphoma: final results of a phase II study [abstract]","volume":"120","author":"Fowler","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"3","key":"2019111704122038700_B17","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"key":"2019111704122038700_B18","article-title":"CALGB 50803(ALLIANCE): A phase 2 trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma [abstract]","volume":"31","author":"Martin","year":"2013","journal-title":"Hematol Oncol (ICML abstracts)"},{"issue":"1","key":"2019111704122038700_B19","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/leu.2012.172","article-title":"Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma","volume":"27","author":"Tilly","year":"2013","journal-title":"Leukemia"},{"issue":"21","key":"2019111704122038700_B20","first-page":"248","article-title":"Lenalidomide in combination with R-CHOP (R2-CHOP) in patients with high burden follicular lymphoma: phase 2 study [abstract]","volume":"122","author":"Tilly","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"8","key":"2019111704122038700_B21","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00277-013-1751-z","article-title":"Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38\/08 trial","volume":"92","author":"Hitz","year":"2013","journal-title":"Ann Hematol"},{"issue":"21","key":"2019111704122038700_B22","first-page":"2700","article-title":"Lenalidomide, bendamustine, and rituximab as first-line therapy for patients > 65 years with mantle cell lymphoma: Results from the phase I portion of the Nordic Lymphoma Group MCL4 (LENA-BERIT) trial [abstract]","volume":"118","author":"Jerkeman","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"20","key":"2019111704122038700_B23","doi-asserted-by":"crossref","first-page":"6446","DOI":"10.1158\/1078-0432.CCR-09-1339","article-title":"Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma","volume":"15","author":"Ansell","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"13","key":"2019111704122038700_B24","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1158\/1078-0432.CCR-10-2660","article-title":"Programmed death ligand 1 is expressed by non-Hodgkin lymphomas and inhibits the activity of tumor-associated T cells","volume":"17","author":"Andorsky","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"33","key":"2019111704122038700_B25","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2012.48.3685","article-title":"Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial","volume":"31","author":"Armand","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111704122038700_B26","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1470-2045(13)70551-5","article-title":"Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial","volume":"15","author":"Westin","year":"2014","journal-title":"Lancet Oncol"},{"issue":"21","key":"2019111704122038700_B27","first-page":"848","article-title":"A phase 2 study of brentuximab vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas: interim results in patients with DLBCL and other B-cell lymphomas [abstract]","volume":"122","author":"Bartlett","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"3","key":"2019111704122038700_B28","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1158\/1078-0432.CCR-13-0226","article-title":"Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia\u2013focus on the B-cell receptor","volume":"20","author":"ten Hacken","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2019111704122038700_B29","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/cmdc.200600221","article-title":"Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase","volume":"2","author":"Pan","year":"2007","journal-title":"ChemMedChem"},{"issue":"1","key":"2019111704122038700_B30","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2162-3619-3-4","article-title":"Ibrutinib for B cell malignancies","volume":"3","author":"Novero","year":"2014","journal-title":"Exp Hematol Oncol"},{"issue":"15","key":"2019111704122038700_B31","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2019111704122038700_B32","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1097\/RLU.0b013e318292a775","article-title":"Anti-CTLA4 antibody therapy related complications on FDG PET\/CT","volume":"39","author":"Koo","year":"2014","journal-title":"Clin Nucl Med"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2014\/1\/169\/1249944\/bep00114000169.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2014\/1\/169\/1249944\/bep00114000169.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T08:45:06Z","timestamp":1717577106000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2014\/1\/169\/20419\/Therapeutic-targeting-of-microenvironment-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,5]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2014.1.169","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,5]]}}}